Phibro Animal Health (NASDAQ:PAHC) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

A number of other research analysts also recently weighed in on PAHC. Zacks Investment Research downgraded shares of Phibro Animal Health from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 24th. ValuEngine downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Monday, November 12th. Three equities research analysts have rated the stock with a sell rating and three have issued a hold rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $43.50.

Shares of Phibro Animal Health stock opened at $32.23 on Tuesday. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of 18.52, a PEG ratio of 3.22 and a beta of 0.75. Phibro Animal Health has a fifty-two week low of $30.79 and a fifty-two week high of $54.62. The company has a debt-to-equity ratio of 1.62, a current ratio of 3.26 and a quick ratio of 1.82.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.39 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.03). The firm had revenue of $200.20 million during the quarter, compared to analyst estimates of $203.99 million. Phibro Animal Health had a return on equity of 38.91% and a net margin of 7.89%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the company posted $0.38 EPS. On average, sell-side analysts predict that Phibro Animal Health will post 1.71 earnings per share for the current year.

In related news, VP Daniel M. Bendheim sold 2,500 shares of the company’s stock in a transaction dated Thursday, January 3rd. The shares were sold at an average price of $31.72, for a total transaction of $79,300.00. Following the completion of the transaction, the vice president now owns 2,500 shares in the company, valued at approximately $79,300. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel M. Bendheim sold 7,500 shares of the company’s stock in a transaction dated Friday, January 18th. The stock was sold at an average price of $32.23, for a total transaction of $241,725.00. Following the transaction, the vice president now owns 2,500 shares of the company’s stock, valued at approximately $80,575. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,560 shares of company stock valued at $1,758,924. Insiders own 50.29% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $115,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $206,000. Jefferies Group LLC purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $215,000. Janus Henderson Group PLC purchased a new stake in Phibro Animal Health during the 2nd quarter valued at about $222,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Phibro Animal Health during the 2nd quarter valued at about $255,000. Hedge funds and other institutional investors own 49.73% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Read More: What is an Initial Public Offering (IPO)?

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.